Premium
Cytopiloyne, a Polyacetylenic Glucoside, Prevents Type 1 Diabetes in Non‐obese Diabetic Mice
Author(s) -
Yang WenChin
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.460
Subject(s) - endocrinology , medicine , diabetes mellitus , lymph , pancreatic islets , type 2 diabetes , islet , t cell , chemistry , immunology , biology , immune system , pathology
Some polyacetylenes from the plant Bidens pilosa have been reported to treat diabetes. Here, we report that cytopiloyne from B. pilosa, structurally different from the above polyacetylenes and inhibits CD4+ T cell proliferation, effectively prevents the development of diabetes in non‐obese diabetic mice, as evidenced by a normal level of blood glucose and insulin and normal pancreatic islet architecture. Cytopiloyne also suppresses the differentiation of type 1 T‐helper cells but promotes that of type 2 T‐helper cells, which is consistent with it enhancing GATA‐3 transcription. As well, long‐term application of cytopiloyne significantly decreases the level of CD4+ T cells inside pancreatic lymph nodes and spleens but does not compromise total antibody responses mediated by T cells. Co‐culture assays imply that this decrease in CD4+ T cells involves the FasL/Fas pathway. Overall, our results suggest that cytopiloyne prevents type 1 diabetes mainly via T cell regulation.